2021
DOI: 10.1016/j.chemosphere.2020.129167
|View full text |Cite
|
Sign up to set email alerts
|

Selection, purification, and evaluation of acarbose−an α-glucosidase inhibitor from Actinoplanes sp.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
17
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 17 publications
(19 citation statements)
references
References 14 publications
2
17
0
Order By: Relevance
“…The lower the IC 50 , the stronger the inhibitory activity. Of the 42 cultivars investigated, 27 cultivars exhibited stronger alpha-glucosidase inhibitory activity with IC 50 values significantly lower than that of acarbose (1.07 mg/mL), which is a widely used drug for the treatment of type-2 diabetes [ 38 ]. Eleven of the cultivars (Berg X Mexican, Blue Motto, Cross X, Ficus Indice, Messina, Nepgen, Ofer, Polypoly, Postmasburg, Roedtan and Sharsheret) demonstrated alpha-glucosidase inhibitory activity (IC 50 < 0.1 mg/mL) that was 10-fold stronger) when compared to acarbose.…”
Section: Resultsmentioning
confidence: 99%
“…The lower the IC 50 , the stronger the inhibitory activity. Of the 42 cultivars investigated, 27 cultivars exhibited stronger alpha-glucosidase inhibitory activity with IC 50 values significantly lower than that of acarbose (1.07 mg/mL), which is a widely used drug for the treatment of type-2 diabetes [ 38 ]. Eleven of the cultivars (Berg X Mexican, Blue Motto, Cross X, Ficus Indice, Messina, Nepgen, Ofer, Polypoly, Postmasburg, Roedtan and Sharsheret) demonstrated alpha-glucosidase inhibitory activity (IC 50 < 0.1 mg/mL) that was 10-fold stronger) when compared to acarbose.…”
Section: Resultsmentioning
confidence: 99%
“…These therapeutic drugs have been widely used in clinical trials because of their own characteristics in hypoglycemic control. For example, α-glucosidase inhibitors have been used to control postprandial glucose levels caused by type 2 diabetes since 1990 (Ríos et al, 2015;Flores-Bocanegra et al, 2017;Santos et al, 2018;Dhameja and Gupta, 2019;Usman et al, 2019;Mi et al, 2021;Tuyen et al, 2021). Acarbose (Chiasson et al, 2002) and miglitol (Satoru et al, 2015), which were clinically used for treating type 2 diabetes, may control blood glucose levels by targeting α-amylases and α-glucosidases (Lyann et al, 2010;Ren et al, 2011).…”
Section: Introductionmentioning
confidence: 99%
“…Acarbose is an AGI, specifically a pseudo-tetrasaccharide that has a nitrogen between the first and second glucose molecules, possessing a particular high affinity for the α-glucosidase enzyme (Tuyen et al, 2021 ). Both enzymes are inhibited in a competitive way, reducing their affinity to the oligosaccharides from dietary starch as well as decreasing the monosaccharide formation rate (Rosak & Mertes, 2012 ).…”
Section: Diabetesmentioning
confidence: 99%